CathWorks, a global leader of digital health innovation focused on helping patients with cardiovascular disease, has appointed Ramin Mousavi as CEO and a member of the company’s Board of Directors. Mousavi succeeds Jim Corbett, who served as the company’s CEO since Oct. 27, 2017.
 
A rising star of the medical device industry, Mousavi has executive leadership and operational experience in general management, marketing, strategy, product development, and commercialization across multiple market segments. Most recently, Mousavi led the patient monitoring and digital health portfolio at Baxter International. Prior to Baxter, he held various leadership assignments at Edwards Lifesciences. Mousavi served as CathWorks vice president of Global Marketing & Strategy and the company’s chief marketing officer from 2019 to 2020.

Mousavi earned bachelor of science degrees in computer and electrical engineering from University of California, Irvine. He also earned an M.B.A. from Paul Merage School of Business at UC, Irvine, and received a Healthcare Executive Leadership certificate for Business Innovation in Global Healthcare from Harvard Business School.
 
“On behalf of the Board of Directors, I would like to thank Jim for his leadership and many important contributions to Cathworks and I am very pleased to welcome Ramin back to our company,” said Scott Ward, board chairman of CathWorks. “Ramin’s extensive knowledge of CathWorks innovative technologies—combined with his proven track record of building high-performing teams that design, develop, and launch breakthrough innovative products and programs that help patients—makes him uniquely positioned to lead CathWorks. The Board is confident that under Ramin’s leadership, CathWorks is well-positioned for our next phase of technology innovation, market adoption, and global commercial growth.”
 
“I am honored and delighted to have the opportunity to lead CathWorks, a company with a transformational product portfolio, exceptionally talented people, and committed investors as well as strategic partners,” commented Mousavi. “CathWorks’ FFRangio technology has the potential to become the standard of care, enhancing the diagnostic decision making of cardiologists around the world. I look forward to working with our clinician partners, employees, the executive management team, and the Board in our mission to provide clinicians with practical, objective physiology information for every patient they treat, and to deliver meaningful value to our patients, customers, and shareholders.”
 
CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize Coronary Artery Disease (CAD) therapy decisions and elevate coronary angiography from visual assessment to an objective FFR-based decision-making tool for physicians. FFR-guided PCI decision-making is proven to provide significant clinical benefits for patients with coronary artery disease and economic benefits for patients and payers. The company’s focus today is specifically on bringing the CathWorks FFRangio System to market to provide quick, precise, and objective intraprocedural wire-free FFR guidance that is practical for every case.